(Q53334056)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

0 references

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Delphine Mérino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Sylvain Audia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Bernard Bonnotte

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Nicolas Larmonier

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Claire Larmonier

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Alexandra Nicolas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Nona Janikashvili

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Andrew Bateman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Jill Thompson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Tim Kottke

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Thomas Hartung

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Emmanuel Katsanis

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Richard Vile

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

language of work or name

English

0 references

publication date

30 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

Experimental Cell Research

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

313

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

2345-2355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Development of anti-TNF therapy for rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Tumor necrosis factor: how to make a killer molecule tumor-specific?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Toxicity of infliximab in the course of treatment of Crohn's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Etanercept plus standard therapy for Wegener's granulomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Specificity of the immune response leading to protection or enhancement by regressive and progressive variants of a rat colon carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Role of tumor cell apoptosis in tumor antigen migration to the draining lymph nodes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loading

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Identification of Tumor-Infiltrating Macrophages as the Killers of Tumor Cells After Immunization in a Rat Model System

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Molecular mechanisms of high-dose antigen therapy in experimental autoimmune encephalomyelitis: rapid induction of Th1-type cytokines and inducible nitric oxide synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Autoimmunity through cytokine-induced dendritic cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Natural-killer cells and dendritic cells: "l'union fait la force".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

TNF-alpha -dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Interaction between two cellular subpopulations of a rat colonic carcinoma when inoculated to the syngeneic host.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

An atypical caspase-independent death pathway for an immunogenic cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Activated peritoneal macrophages inhibit the proliferation of rat ascites hepatoma AH-130 cells via the production of tumor necrosis factor-alpha and nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Induction of anergic and regulatory T cells by plasmacytoid dendritic cells and other dendritic cell subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Transforming growth factor-beta produced by progressor tumors inhibits, while IL-10 produced by regressor tumors enhances, Langerhans cell migration from skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2007.03.027

10.1016/J.YEXCR.2007.03.027

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17466973%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference